New FDA head needs to examine the accelerated approval program
World of DTC Marketing
OCTOBER 21, 2021
A separate analysis by the same research team, also published Monday by JAMA Internal Medicine, found that in 2018, nearly 60% of cancer patients with private insurance nationally received an oral targeted treatment that did not lead to improved overall survival in clinical trials.
Let's personalize your content